Oral magnesium supplements and insulin resistance in individuals with diabetes and pre-diabetes: an updated systematic review and meta-analysis of randomized controlled trials
Abstract
Diabetes is a common health challenge. Previous studies have established that diabetes is often associated with low circulating magnesium status. As evidence from randomized controlled trials (RCTs) on the effect of magnesium supplementation on insulin resistance remains inconsistent, and the influence of baseline status is not fully understood, this systematic review and meta-analysis evaluated the effects of magnesium supplements, compared with placebo, on insulin resistance in individuals with diabetes and pre-diabetes. A comprehensive search based on the PRISMA 2020 guidelines was conducted in PubMed, Web of Science, and Scopus until 24 April 2026. Randomized controlled trials with a population of individuals with diabetes and pre-diabetes that received any magnesium supplements compared to a placebo group, evaluating insulin and the HOMA-IR index as the primary outcome, were included in our study. Secondary outcomes were serum magnesium level, HbA1c, and fasting blood glucose (FBG). We pooled data using a random-effects model to estimate changes in outcomes. Subgroup analyses were conducted based on dosage (> 250 and ≤ 250 mg/day) and follow-up duration (under or over 12 weeks). Meta-regression, publication bias, and sensitivity analysis were performed as well. Fifteen RCTs involving 1,085 participants met the criteria. Overall, the oral magnesium supplementation did not result in a statistically significant change in insulin levels (MD = − 1.73; 95% CI: −3.73 to 0.27;…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,085 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.